125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
|
|
|
- いおり やぶき
- 7 years ago
- Views:
Transcription
1 . (1) Renagel PB-94 P intact-pth P 1 b c a b P 4 D HIV Hb 8.0g/dL ALT 48IU/L 6 7 PB mg 403mg 1-196
2 125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca mg/ Ca 2 Ca Ca 900mg/1500mg/ 1 Ca P Mg Na K Cl LDH AST ALT T-Bil ALP T-Cho LDL-Cho HDL-Cho TG TPAlb BUN Cr UAHCO 3 Fe TIBCintact-PTH 2 Plt 3 PT APTT 4 A 1,25(OH) 2 D 25(OH)D E 5HCG P 2T-Cho LDL-Cho HDL-Cho TG intact-pth 2 Not RelatedRemotePossibly Related Probably Related Possibly RelatedProbably Related -197
3 p t intact-pth Wilcoxon st washout 2nd washout ,2, P Ca HCG
4 P PB-94 kg P PTx D D Kt/V (n=191) Ca meq/l 127 n=192 Range Mean S.D. Median Range Mean S.D. Median African-American Caucasian Hispanic Asian PB-94 Ca Ca Al Ca Al Range Mean S.D. Median Range Mean S.D. Median %
5 D D % % % Ca % Ca % % 5.95g/ 5.02g/ 6 1 P Mean S.D. P 62 P mg/dL mg/dL mg/dL t t= p<012nd washout P mg/dL t t=8.880 p< 血清 P 濃度 (mg/dl) ( 週 ) 62 P Mean S.E. -200
6 2 Ca Mean S.D. Ca 63 Ca mg/dL mg /dl mg/dL t t=5.100 p<01 1 Camg/dL ( 週 ) 63 Ca Mean S.E. 3 Ca P Mean S.D. Ca P 64 Ca P mg/dl mg/dl mg/dl 2 t t=-105 p< Ca P 積 (mg/dl) Ca P Mean S.E. -201
7 4 intact-pth Median intact-pth 128 intact-pth 286.5pg/mL 254.0pg/mL 128 intact-pth pg/ml Wilcoxon n u p , , , Median 25,75% T-Cho LDL-Cho HDL-Cho TG 129 mg/dl n t t p T-Cho <01 LDL-Cho <01 HDL-Cho <01 TG Mean S.D. -202
8 % % % % % NOS 8 4.2% NOS 1 1 NOS MedDRA SOC MedDRA PT % * 4 3 4,3 2, NOS NOS NOS NOS NOS NOS 0 1 NOS NOS NOS NOS 0 1 NOS NOS NOS NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -203
9 MedDRA SOC 130 MedDRA PT % * 4 3 4,3 2, NOS NEC NOS NEC NEC NEC NOS NOS NOS NOS NOS NOS NOS 0 1 NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -204
10 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2,1 NOS NOS 0 1 NOS NOS NOS 0 1 NOS NOS NOS NOS NOS NOS NOS NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -205
11 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2, NOS NOS NOS 0 2 NOS NOS NOS NOS NOS 0 1 NOS 0 3 NOS NOS NOS 0 2 NOS NOS NOS NOS 0 1 NOS 0 2 NOS NOS NOS 0 3 NOS 0 2 NOS 0 1 NOS NOS 0 1 NOS NOS 0 1 NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -206
12 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2,1 NOS NOS 0 1 NOS NOS NOS NOS 0 3 NEC NOS 0 1 NOS NOS NOS 0 1 NOS NOS NOS NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -207
13 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2,1 TG NOS 0 1 NOS NOS INR 0 1 NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS 0 1 * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -208
14 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2,1 0 1 NOS NOS NOS 0 1 NOS NOS NOS NOS NOS NOS 0 2 NOS NOS NEC 0 2 NOS NOS 0 2 NOS 0 1 NOS NOS NEC NEC NOS 0 1 NEC NEC NEC * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -209
15 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2,1 NEC NOS NEC NOS NOS NOS NOS NOS 0 1 NOS 0 1 NOS NOS 0 1 NOS NOS NOS NOS NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -210
16 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2,1 NOS NOS NOS NEC NOS NOS NOS NOS NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -211
17 130 MedDRA SOC MedDRA PT % * 4 3 4,3 2, NOS 0 1 NOS 0 1 NOS 0 1 NOS NOS NOS NOS NOS NOS NOS 0 1 NOS NOS NOS * 4 Probably Related 3 Possibly Related 2 Remote 1 Not Related -212
18 131 MedDRA SOC MedDRA PT % () 1 () NOS 1 () 1 () 1 () 1 () 1 () 1 () 1 () 1 () 2 () 2 () NOS 2 () 1 () 3 () 4 (2.1) 2 () 6 (3.1) 2 () 2 () 4 (2.1) NOS 4 (2.1) 3 () 7 (3.6) 7 (3.6) 3 () 1 () 11 (5.7) 1 () 1 () 1 () 1 () 4 (2.1) 1 () 1 () 6 (3.1) 1 () 1 () 1 () 1 () 5 (2.6) 9 (4.7) 14 (7.3) 1 () 1 () 1 () 1 () NOS 2 () 6 (3.1) 8 (4.2) 1 () 1 () 1 () 1 () 1 () 1 () NOS 1 () 1 () 1 () 1 () 1 () 1 () 1 () 1 () NOS 1 () 1 () 1 () 1 () NOS 1 () 1 () NOS 2 () 2 () 2 () 2 () 1 () 1 () 3 () 3 () 1 () 3 () 4 (2.1) 1 () 1 () 1 () 1 () NOS 1 () 1 () NOS 1 () 1 () NOS 1 () 1 () 1 () 1 () 1 () 1 () 1 () 1 () 1 () 1 () NOS 1 () 1 () 1 () 1 () NOS 1 () 1 () NOS 1 () 1 () 2 () 1 () 1 () NOS 1 () 1 () 1 () 1 () -213
19 % % % % % % % % -214
20 132 MedDRA SOC MedDRA PT / / / / / / / / / / / / NOS NOS NOS NOS NOS NOS 1 1 NOS NOS NOS NOS 1 1 NOS NOS NOS NOS NOS NEC NOS NEC NEC NEC NOS NOS NOS NOS NOS NOS NOS
21 132 MedDRA SOC MedDRA PT NOS NOS NOS NOS NOS NOS 1 1 NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS 1 1 NOS NOS NOS NOS
22 132 MedDRA SOC MedDRA PT NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS 1 1 NOS NOS NOS NOS NOS 1 1 NOS NOS NOS NOS NEC NOS NOS NOS NOS 1 1 NOS NOS NOS NOS
23 132 MedDRA SOC MedDRA PT TG NOS 1 1 NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
24 132 MedDRA SOC MedDRA PT NOS 1 1 NOS 1 1 NOS NOS NOS NOS NOS NOS NOS NEC NOS NOS NOS NOS NOS NEC NEC NOS 1 1 NEC NEC NEC NEC NOS NEC NOS NOS NOS NOS NOS 1 1 NOS NOS NOS 1 1 NOS NOS
25 132 MedDRA SOC MedDRA PT NOS NOS NOS NOS NOS NOS NEC NOS NOS NOS NOS NOS NOS NOS 1 1 NOS NOS NOS NOS
26 132 MedDRA SOC MedDRA PT NOS NOS NOS NOS 1 1 NOS NOS NOS MedDRA SOC MedDRA PT / / / / / / / / / / / / NOS NOS NOS NOS NOS NOS NOS NOS NOS 1 1 NOS NOS NOS NOS 1 1 NOS NOS
27 st washout 5 2.6% % 154 2nd washout % 24 Remote Not Related 2 1 NOS % Not Related %2 NOS NOS NOS NOS NOS NOS 1 NOS NOS NOS Not Related Na UA BUN Cr Hb MCHC WBC Lympho Plt A 25(OH)D E Cl HCO 3 Mg FeALP MCV 1,25(OH) 2 D 134 t t p RBC 10 4 /µl ± ± ± MCV fl ± ± ± MCH pg ± ± ± MCHC % ± ± ± <01 Hb g/dl ± ± ± Ht % ± ± ± Plt 10 4 /µl ± ± ± <01 WBC /µl ± ± ± Neu % ± ± ± Lympho % ± ± ± Mono % ± ± ± Eosino % ± ± ± Baso % ± 2 3 ± 7-7 ± Alb g/dl ± ± ± TP g/dl ± ± 9-5 ± mg/dl ± ± ± g/dl ± ± 7-3 ± AST IU/L ± ± ± ALT IU/L ± ± 22.0 ± LDH IU/L ± ± ±
28 134 t t p ALP IU/L ± ± ± <01 T-Bil mg/dl ± ± ± BUN mg/dl ± ± ± <01 Cr mg/dl ± ± ± UA mg/dl ± ± ± <01 Na meq/l ± ± ± K meq/l ± ± ± Cl meq/l ± ± 4.3 ± <01 Mg mg/dl ± ± ± <01 HCO 3 meq/l ± ± ± <01 mg/dl ± ± ± PT ± ± ± APTT ± ± ± Fe µg/dl ± ± ± TIBC µg/dl ± ± 95.1 ± % ± ± ± <01 ng/ml ± ± ± <01 ng/ml ± ± ± A ng/ml ± ± ± ,25(OH) 2 D pg/ml ± ± ± <01 25(OH)D ng/ml ± ± ± <01 E mg/dl ± ± ± Mean±S.D. 8 P Ca T-Cho LDL-Cho -223
29 (2) b b Renagel PB-94 P intact-pth P P 4 D HIV Hb 8.0g/dL ALT 48IU/L PB PB mg 1 2 P 1st washout 2 1st washout P 6.0mg/dL PB-94 1st washout P -224
30 135 b P 6.0mg/dL< <7.5mg/dL 7.5mg/dL <9.0mg/dL 9.0mg/dL P mg/dL P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D Ca 3 Ca Ca 4 2nd washout 2 1 Ca P Mg Na K Cl LDH AST ALT T-Bil ALP ALP T-Cho LDL-Cho HDL-Cho TG TPAlb Fe TIBCBUN Cr UAHCO 3 intact-pth 2 Plt 3 PT APTT 4 A D E 5 HCG P 2T-Cho LDL-Cho HDL-Cho TG intact-pth 2 Not RelatedRemotePossibly Related Probably Related Possibly RelatedProbably Related -225
31 135 b p Wilcoxon 3 2 Wilcoxon st washout 2nd washout P Ca intact-pth HCG ITT % 25 D 8 Ca Ca PC -226
32 ITT 168 ITT 4 PC 107 PC ITT n=168 kg P PTx % 110(65.5) 58(34.5) Range Mean±S.D Median 52.0 Range Mean±S.D Median 77.3 African-American Caucasian Hispanic Asian Ca Ca Al Al Ca Al Ca
33 137 % Range <-2 Mean±S.D Median 3.0 D D Range Kt/V Mean±S.D Median Ca meq/l % g/Mean S.D.1 465mg hydrous 4 1 P Mean S.D. P 66 P mg/dL mg/dL mg/dL Wilcoxon p<01 66 P Mean S.E. -228
34 32 P 2 P PC P P 138 P P P P 138 P P PC n=107 /g/ n P Mean S.D P 1st washout 5.5mg/dL % %6.98g/15cap/ g/18cap/ % Kaplan- Meier product limit curve 5.12g/ 50% 139 ITT n=168 / g/ n % n % n % n % n % n % n %
35 4 Ca Mean S.D. Ca 67 Ca mg/dL mg/dL 0.3 mg/dl Wilcoxon p<01 1st washout 67 Ca Mean S.E. 5 intact-pth Mean±S.D. intact-pth 140 intact-pth pg/mL pg/mL n 140 intact-pth pg/ml Median(25,75%) Mean±S.D. Mean S.D. Wilcoxon p 1st washout , ± , ± , ± ±169.3 < , ± ±165.9 < , ± ±213.5 < , ± ±221.5 <01-230
36 6 141 T-Cho LDL-Cho HDL-Cho TG 141 mg/dl n Wilcoxon p T-Cho ± ± ±28.2 <01 LDL-Cho ± ± ±26.4 <01 HDL-Cho ± ±13.3 ± TG ± ± ± Mean S.D. 5 Coding Symbols for Thesaurus of Advers Reaction Terms COSTART Third Edition % % % % % % % % % % % % % % n %
37 142 n % Hb st washout 2 1.2% % 33 2nd washout 8 4.7% 9 Not Related Remotely Related 3 1.7%1st washout 1 2nd washout Not Related 3 Na UA LDH TP ALP-2 BUN Cr Ht RBC Lympho PT INR A 25 OH D Cl Mg TIBC ALP MCH MCHC Neu 6 P Ca 1st washout intact-pth T-Cho LDL-Cho -232
38 (3) Ca Ca Renagel PB-94 P Ca P intact-pth Ca Ca P intact-pth OC ALP ICTP P P 4 D P 8.0mg/dL 9 PB-94 Ca Ca HIV kg
39 143 10Hb8.0g/dL ALT PB-94 1 PB mg 2 Ca 1 500mg mg 1 2 P washout 2 washout 1 P 5.5mg/dL PB-94 P P mg/dL Ca 1mg/dL P 3.0mg/dL P P 2 D 12 D intact-pth 300pg/mL D 3 Ca Ca 8.5mg/dL 24 D 3 intact-pth 300pg/mL Ca 4 1 Ca P Mg Na K Cl LDH AST ALT T-Bil ALP ALP OC ICTP T-Cho LDL-Cho HDL-Cho TG TPAlb BUN Cr UAHCO 3 Fe TIBCintact-PTH 2 Plt 3 PT APTT -234
40 143 4HCG 5 Electron Beam Tomography EBT 1 EBT X helical CT CT EBT X CT X 1 100msec 0.1 EBT 2 EBT Imatron C-100 C-150 EBT R-R 60 80% mm EBT CT 130Hounsefield Units HU 1 CT 130HU 3 3mm 2 Calcification volume Agatston score R-4 Calcification volume EBT Agatston score Calcification volume CT Calcification volume Agatston score Calcification volume Agatston score Calcification volume Agatston score R Calcification volume Agatston score EBT EBT EBT R-6-235
41 143 1 Calcification volume/agatston score Calcification volume Agatston score None 0 Mild/Moderate Severe Very Severe > Calcification volume/agatston score Calcification volume Agatston score None 0 First tirtile Low Second tirtile Middle Third tirtile High P Ca P intact-pth 2 Ca Ca Ca 1mg/dL 1mg/dL P P 5.0mg/dL intact-pth pg/mL 2 Not RelatedRemotePossibly Related Probably Related Possibly RelatedProbably Related PB p 5 1 Fisher Wilcoxon -236
42 143 2 Wilcoxon Wilcoxon P Ca intact-pth Fisher 3 Fisher Wilcoxon 15 washout P Ca intact-pth ALP OC ICTP HCG EBT -237
43 1 202 PB PB-94 1 PB % PB PB PB PB PB PB PB
44 n=200 PB-94 n=99 n=101 n= Range Mean Median Mean kg Median Caucasian African-American Hispanic Asian Ca Ca Al Ca Al Al Ca P PB PB-94+ Ca PB-94+ Ca PB-94+Al Ca PTx Mean Median D Ca meq/l * Wilcoxon Fisher p
45 3 202 PB PB PB PB-94 86% 80% PB g/ 4.32g/ 5 1 P Mean P 69 P P PB mg/dL 5.2mg/dL PB mg/dL p<01-2.0mg/dl p<01 Wilcoxon Wilcoxon p= Serum Phosphorus P mg/dl (mg/dl) Renagel PB-94 C alcium Screening Study Week 69 P Mean S.E. 2 P P 5.0mg/dL P PB-94 83% 63/76 86% 70/81 P PB-94 54% 41/76 52% 42/81-240
46 3 Ca Mean Ca 70 Ca PB mg/dL 9.74mg/dL PB-94-16mg/dL p= mg/dl p<01 Wilcoxon Ca Wilcoxon p<01 1 Serum Ca Calcium mg/dl (mg/dl) PB-94 Renagel Calcium 8.5 Screening Study Week 70 Ca Mean S.E. 4 Ca Ca 1mg/dL 1 Ca 1mg/dL PB-94 17% 13/76 43% 35/81 Fisher p<01 Ca 1mg/dL PB-94 5% 4/76 16% 13/81 Fisher p=39 Ca 1mg/dL 1 Ca 1mg/dL PB-94 5% 4/76 20% 16/81 Fisher p=07 Ca 1mg/dL PB-94 3% 2/76 4% 3/81 Fisher p=00-241
47 5 Ca P Mean Ca P 71 Ca P PB mg/dl mg/dl 2 PB mg/dl 2 p< mg/dl 2 p<01 Wilcoxon Ca P PB-94 Ca P Wilcoxon p=0.104 Serum Calcium Ca P x Phosphorus mg/dl Product 2 (mg 2 /dl 2 ) 75 Renagel PB Calcium Screening Study Week 71 Ca P Mean S.E. 6 intact-pth Median intact-pth 146 washout intact-pth PB pg/mL pg/mL washout intact-pth PB pg/mL 200pg/mL PB-94 intact-pth pg/mL pg/mL pg/mL intact-pth intact-pth 146 intact-pth pg/ml n Mean Median Mean p * washout PB washout <01 * Wilcoxon **Wilcoxon p **
48 7 intact-pth pg/mL intact-pth PB-94 75% 57/76 64% 52/81 Fisher p=0.119 intact-pth PB-94 37% 28/76 25% 20/81 Fisher p= Mean OC ALP 147 OC ALP PB-94 OC PB ng/mL 15.80ng/mL p<01 ALP PB U/L 6.81U/L p<01 Wilcoxon ICTP 147 OC ALP n Mean Median OC ng/ml ALP U/L PB-94 PB PB-94 T-Cho LDL-Cho HDL-Cho TG 148 mg/dl n p * T-Cho LDL-Cho HDL-Cho TG *Wilcoxon PB p< N.S. PB p< N.S. PB N.S N.S. PB N.S N.S. Mean -243
49 10 Calcification volume Agatston score 149 Calcification volume Median PB PB Calcification volume PB-94 Agatston score Median PB PB Agatston score PB-94 Calcification volume Agatston score EBT Calcification volume Agatston score PB-94 PB-94 p * n=92 n=94 n=92 n=94 p * n (%) Mean Median n (%) Mean Median n (%) Mean Median n (%) Mean Median n (%) Mean Median n (%) Mean Median * Wilcoxon -244
50 150 Calcification volume MedianPB Agatston score MedianPB PB-94 Calcification volume Agatston score Mild/ Moderate PB n Calcification volume Agatston score PB-94 p * PB-94 p * n Mean Median n None Mean Median n Mild Mean /Moderate Median n Severe Mean Median n Very Severe Mean Median n Mean Median n None Mean Median n Mild Mean /Moderate Median n Severe Mean Median Very Severe Mean Median * Wilcoxon -245
51 151 Calcification volume MedianPB Agatston score MedianPB PB-94 Agatston score Third Tirtile PB n Calcification volume Agatston score PB-94 p * PB-94 p * n Mean Median n None Mean Median n First Mean Tirtile Median n Second Mean Tirtile Median n Third Mean Tirtile Median n Mean Median n None Mean Median n First Mean Tirtile Median n Second Mean Tirtile Median Third Tirtile * Wilcoxon Mean Median
52 R-5 Calcification volume Median PB % 28.45% Agatston score Median PB % 25.38%PB-94 Calcification volume PB % 37.10% PB-94 Agatston score PB % 28.36%PB % Calcification volume Agatston score PB-94 p * PB-94 p * n Mean Median n Mean Median n Mean Median Mean Median * Wilcoxon n Calcification volume Agatston score 0-247
53 6 1 PB % % 199 PB % 55.4% p=11 Fisher PB % 47.5% p=09 Fisher PB % 38.6% p=14 Fisher PB-94 NOS % 33 NOS % 32 PB % 6.9% p=47 Fisher PB % 17.8% p=02 Fisher 153 PB % % MedDRA SOC PB-94 n=99 n=101 % % p * *Fisher -248
54 2 PB possibly related PB-94 1 PB-94 S 250mm 20mm S PB Cl PB mEq/L -0.47mEq/L p<01 Wilcoxon CO 2 PB mEq/L 3.57mEq/L p<01 Wilcoxon UA PB mg/L -0.26mg/L p=01 Wilcoxon TIBC PB mcg/dL mcg/dL p=07 Wilcoxon ALP PB U/L 4.10U/L p<01 Wilcoxon -249
55 7 EBT Agatston score Calcification volume Agatston score MedianPB PB-94 p=39 Agatston score Median PB PB-94 p=10 Calcification volume PB-94 P Ca Ca Ca P PB-94 Ca intact-pth PB-94 intact-pth 150~300pg/mL intact-pth Ca P LDL-Cho R-7-250
56 P Ca P Ca R-8, 9 4.2% %
57 QOL R-10 R-11 mg/ mg/ mg/ mg/ kcal/kg/ g/kg/ ml/ /kg /kg Na b n=51 b n=129 mg/ mg/ mg/ mg/ kcal/ g/ g/ Mean S.D. 3 R-12, ,
58 P P 250mg 440mg 403mg P 4.0 P 6mg/dL P 2.5 P 5.5mg/dL Ca D P P 158 % n=157n= kg D Ca Ca Al Ca AlCa PB Ca Mean S.D. -253
59 3 P Ca Mean S.D. P washout washout PB-94 n= washout mg/dL P mg/dL mg/dL mg/dL mg/dL mg/dL Ca washout mg/dL mg/dL 4 8mg/dL mg/dL mg/dL mg/dL P Ca g/ n Mean Min Max ICH Medical Dictionary for Regulatory ActivitiesMedDRA Ver % 157/ % 187/ % 84.1% 54.1% 73.4% -254
60 70.8% 62.0% 26.1% 24.8% 24.8% 22.3% NOS 17.2% 35.4% NOS 33.3% NOS 25.0% 17.7% 160 % MedDRA SOC MedDRA SOC /
61 % 113/ % 49/ % 20.3% 10.8% 2.1% R-14 R % NOS % 19.7% 15.9% 9.6% 5.7% 7.3% 5.7% NOS 4.2% 1 250g 1 8 9g 45%R-16 R-17 S 40% R-18 59% R-1971% R % 43.3% 28.6% NOS NOS
62 Cu Zn 2 3 ALP 5 MedDRA SOC 161 % MedDRA SOC
63 2 % NOS % 2 NOS NOS NOS 1 NOS NOS NOS 1 NOS NOS NOS Not related 9.2% % % % T-Cho LDL-Cho HDL-Cho ALP Cl 3. P Ca -258
64 -259
65 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
66 % n= n=192 % NOS NOS NOS / NEC NOS NOS NOS NEC NEC NOS NEC NOS
67 % n= n=192 % NEC NOS NOS NOS NOS NOS NOS
68 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
69 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
70 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
71 % n= n=192 % NOS NEC NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
72 % n= n=192 % NOS NOS 2 NOS NOS NOS ph NOS B 12 PO
73 % n= n=192 % ph C- PO 2 X NOS NOS NOS NOS - NOS INR NOS
74 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS NOS
75 % n= n=192 % NOS NOS NOS NOS NOS NOS ( ) NOS NOS NOS NOS NOS NOS NOS NEC NEC NEC NOS
76 % n= n=192 % NOS NOS NEC NOS NOS NEC NOS NOS NOS NEC NEC NEC NOS NOS NOS NOS
77 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
78 % n= n=192 % NOS NOS NOS NEC NOS NOS NOS NOS NOS NOS
79 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS NOS
80 % n= n=192 % NOS NOS NOS NOS NOS NOS NOS
81 n= % 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W n= %
82 W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W n= % n= %
83 W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W n= % n= %
84 W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W n= % n= %
85 n= % n= % 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W
86 W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W n= % n= %
87 W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W n= % n= %
88 W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W 1 4W 5 8W 9 12W 13 16W 17 20W 21 24W 25 28W 29 32W 33 36W 37 40W 41 44W 45 48W ( n= % n= %
89 n t t p 192 n t t p mmhg ± ± 21.7 ± 17.9 <01 00 mmhg ± ± ± kg ± ± ± <01 kg ± ± ± <01 RBC 10 4 /µl ± ± ± ± ± ± MCV fl ± ± ± MCH pg ± ± ± MCHC % ± ± ± <01 Hb g/dl ± ± ± ± ± ± Ht % ± ± ± ± ± ± Pt 10 4 /µl ± ± ± ± ± ± <01 WBC /µl ± ± ± ± ± ± Neu % ± ± ± Lympho % ± ± ± Mono % ± ± ± Eosino % ± ± ± Baso % ± 2 3 ± 7-7 ± P mg/dl ± ± ± < ± ± ± <01 Ca mg/dl ± ± ± <01 Ca mg/dl ± ± ± <01 Ca P mg/dl ± ± ± < ± ± ± <01 Alb g/dl ± ± ± ± ± ± TP g/dl ± ± ± < ± ± 9-5 ± g/dl ± ± 7-3 ± AST IU/L ± ± ± ± ± ± ALT IU/L ± ± ± ± ± 22.0 ± LDH IU/L ± ± ± ± ± ± ALP IU/L ± ± ± < ± ± ± <01 T-Cho mg/dl ± ± ± < ± ± ± <01 HDL-Cho mg/dl ± ± ± < ± ± ± <01 LDL-Cho mg/dl ± ± ± < ± ± ± <01 TG mg/dl ± ± ± ± ± ± T-Bil mg/dl ± ± 9 1 ± ± ± ± BUN mg/dl ± ± ± < ± ± ± <01 BUN mg/dl ± ± ± Cr mg/dl ± ± ± ± ± ± UA mg/dl ± ± ± < ± ± ± <01 Na meq/l ± ± ± ± ± ± K meq/l ± ± 5 4 ± ± ± ± Cl meq/l ± ± ± < ± ± 4.3 ± <01 Mg mg/dl ± ± ± ± ± ± <01 ph ± ± ± <01 HCO 3 meq/l ± ± ± < ± ± ± <01 Mean S.D. -284
90 n t t p n t t p mg/dl ± ± ± po 2 torr ± ± ± pco 2 torr ± ± ± <01 PT ± ± ± ± ± ± APTT ± ± ± ± ± ± Kt/V ± ± ± PCR g/ ± ± ± <01 intact-pth pg/ml ± ± ± ± ± ± A/G ± ± ± <01 Fe µg/dl ± ± ± ± ± ± UIBC µg/dl ± ± ± <01 TIBC µg/dl ± ± ± % ± ± ± <01 ng/ml ± ± ± <01 Cu µg/dl ± ± ± Zn µg/dl ± ± ± µmol/l ± ± ± ng/ml ± ± ± ± ± ± ALP-1 % ± ± ± <01 ALP-2 % ± ± 12-5 ± ALP-3 % ± ± ± <01 ALP-4 % ± 0 0 ± 0 0 ± 0 ALP-5 % ± ± ± <01 ALP-6 % ± 0 0 ± 0 0 ± 0 ALP% ± 0 0 ± 0 0 ± 0 ALP U/L ± ± ± <01 OC ng/ml ± ± ± PICP ng/ml ± ± ± <01 A ng/ml ± ± ± ± ± ± B 12 pg/ml ± ± ± ,25(OH) 2D pg/ml ± ± ± ± ± ± <01 24,25(OH) 2D ng/ml ± ± ± <01 25(OH)D ng/ml ± ± ± < ± ± ± <01 E mg/dl ± ± ± < ± ± ± Mean S.D. -285
91 . 1mm 250mg1mm 9.0mm 250mg9.0mm in vitro 4 P 1mm 9.0mm P 1 6 1mm mm 1 6 1mm mm 1 1 P 6.0mg/dL 2 1 P 1mg/dL 3 1 Ca 1mg/dL 4 2 P % 6 3.0g/ P 8.0mg/dL 6.0g/ P 8.0mg/dL 7 PB g/ 6.0g/ 3.0g/6.0g/1mm 9.0mm 2 P 1mm mm g/1mm mm g/1mm 9 9.0mm mm -286
92 P P g/ 6.0g/ P D P mg/dl 163 1mm n=20 9.0mm n=99 n= Range Mean S.D Median Range Mean S.D Median P mg/dl n 3.0g/ 6.0g/ 1mm mm 62 1mm 9 9.0mm 37 95%CI %CI Mean S.D mm 1mm 250mg mm 200mg 9.5mm 250mg 1mm 300mg 1mm -287
93 400mg 12.0mm 500mg 1mm 500mg 12.0mm mm 9.5mm R-21 1mm 250mg 9.0mm 250mg 165 n 9.0mm 9.5mm 1mm 1mm 12.0mm % -288
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
<8C9F8DB85F3338E4508CB495612E786C73>
尿 検 査 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり 随 時 尿 蛋 白 ( 定 性 ) - - - 糖 ( 定 性 ) - - - 潜 血 ( 定 性 ) - - - 項 目 に が 付 与 されている 場 合 : 該 当 の 項 目 は 1/5 尿 検 査 血 球 算 定 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり WBC ( )
日本呼吸器学会雑誌第47巻第6号
Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
Gifu University Hospital Cancer Center 1 2 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center 3 4 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center
日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
001-029_”÷’X
54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54
Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
血糖高いのは朝食後のため検査項目 下限値上限値 単位名称 9 月 3 日 9 月 6 日 9 月 15 日 9 月 18 日 9 月 21 日 9 月 24 日 9 月 28 日 10 月 1 日 10 月 3 日 10 月 5 日 10 月 9 日 10 月 12 日 10 月 15 日 10 月
検査項目 下限値上限値 単位名称 7 月 9 日 7 月 10 日 7 月 11 日 7 月 12 日 7 月 13 日 7 月 17 日 7 月 20 日 7 月 23 日 7 月 25 日 7 月 27 日 7 月 30 日 8 月 3 日 8 月 6 日 8 月 8 日 8 月 10 日 8 月 12 日 8 月 15 日 8 月 17 日 8 月 20 日 8 月 22 日 8 月 24 日
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
生化学検査 臨床検査基準値一覧 近畿大学病院 (1) 検査項目 基準値 単位 検査項目 基準値 単位 CRP mg/dl WBC /μl Na mmol/l M RBC K mmol/l F 3.86-
生化学検査 近畿大学病院 (1) CRP 0.00-0.14 WBC 3.3-8.6 10 3 /μl Na 138-145 mmol/l M 4.35-5.55 RBC K 3.6-4.8 mmol/l F 3.86-4.92 10 6 /μl Cl 101-108 mmol/l M 13.7-16.8 HGB g/dl Ca 8.8-10.1 F 11.6-14.8 Pi 2.7-4.6 液 M
72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
日本呼吸器学会雑誌第44巻第6号
Aspergillus β Table1 Laboratoryfindingsonadmission Hematology WB Seg Band Lymph Eos Baso RB Hb Hct Plt Biochemistry AST ALT LD ALP γ-gtp K 17,700 /mm 3 70.0 % 7.0 % 17.0 % 2.0 % 1.0 % 337 10 4 /mm 3 11.5g/dl
日本呼吸器学会雑誌第44巻第7号
Table1Laboratoryfindingsonadmission Hematology Serology LungFunctionTest WBC 7,410 /μl CRP 7.7mg/dl VC 3.12L(97.2%) Neut 66.4 % KL-6 777U/ml FEV1.0 2.35L(78.25%) Eosino 3.2 % PT (INR) 0.94 %DLCO 47.6 %
日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
ケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1
59 20 : 50 : 2005 9 : 2006 1 : 2006 4 : :2 / :20 / 25 GTP 2006 1 4/28 5/35/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3:78 / :156/78mmHg 1 0.3g 1 30-49 Hb9.5g/dL 7 /mm 3 - Cr1.6mg/dL CRP1.84 mg/dl
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
基準値一覧 ( 平成 24 年 6 月 1 日 ) 独立行政法人国立病院機構東京医療センター 臨床検査科
基準値一覧 ( 平成 24 年 6 月 1 日 ) 独立行政法人国立病院機構東京医療センター 臨床検査科 項目名 検査法 単位 基準値 M F TP ビュレット法 g/dl 6.3~8.2 ALB BCG 法 g/dl 3.5~5.2 A/G 演算 1.26~2.26 ZTT 硫酸亜鉛混濁 KU 4.0~12.0 TBIL 酵素法 mg/dl 0.30~1.20 DBIL 酵素法 mg/dl 0.00~0.30
<8C9F8DB889C88AEE8F80926C88EA A E342E312E786C73>
基準値一覧 ( 平成 27 年 4 月 1 日 ) 独立行政法人国立病院機構東京医療センター 臨床検査科 項目名 検査法 単位 基準値 M F TP ビュレット法 g/dl 6.3~8.2 ALB BCG 法 g/dl 3.5~5.2 A/G 演算 1.26~2.26 ZTT 硫酸亜鉛混濁 KU 4.0~12.0 TBIL 酵素法 mg/dl 0.30~1.20 DBIL 酵素法 mg/dl 0.00~0.30
エディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
untitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
当院の血液検査室の概要 血液検査 system 自動血球分析装置塗抹標本作製装置 La-vietal LS (Sysmex 社 ) XN-3000 (Sysmex 社 ) XN 台 ( RET WPC PLT-F の各チャンネル ) XN 台 SP-10 (Sysmex
いまさら聞けないシリーズ CBC スキャッタから目視血液像を追加するポイント 済生会習志野病院検査科深海律子 当院の血液検査室の概要 血液検査 system 自動血球分析装置塗抹標本作製装置 La-vietal LS (Sysmex 社 ) XN-3000 (Sysmex 社 ) XN-2000 1 台 ( RET WPC PLT-F の各チャンネル ) XN-1000 1 台 SP-10 (Sysmex
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
AD-5423_2
/ 2 /2.7 /CTD 8 8 II II 1 2 6 mg/ 6 mg/ HIV C 80 mmhg 3 1 3 80 mmhg 31 / 2 /2.7 /CTD 8 8 II II 1 2 3 23 32 / 2 /2.7 /CTD 2.7.3.3.1-28 123 2.7.3.3.1-2 8 1 2 3 2.7.3.3.1-3 2.7.3.3.1-48 2.7.3.3.1-5 40 5 7
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
08症例報告4山内.indd
症例報告 37 急性大動脈解離に対する上行大動脈置換術後の大動脈基部拡張 大動脈弁閉鎖不全に対する自己弁温存基部置換術 (remodeling 手術 ) 概要 : mm remodeling 索引用語 : remodeling Remodeling technique for aneurysm of aortic root and moderate aortic valve regurgitation
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
Microsoft PowerPoint - 当日H3001標準化報告会用hiramitu.pptx
平成 29 年度社団法人岐阜県臨床検査技師会精度管理報告会 標準化事業総括 平光幹彦 ( 岐阜市民病院 ) 精度管理調査結果報告 ( 標準化事業総括 ) 岐阜県総参加施設数 病院 診療所 51 検査センター 9 試薬メーカー 20 昨年より 病院 診療所で 4 施設増 日臨技の精度管理事業昭和 45 年から外部精度管理調査を開始全国参加施設 3800 施設以上現在 742 施設認証 1 項目 29
JAJP
Agilent 7500ce ORS ICP-MS Glenn Woods Agilent Technologies Ltd. 5500 Lakeside, Cheadle Royal Business Park Stockport UK Agilent 7500ce ICP-MS 5 7500ce (ORS) 1 ORS 7500ce ORS ICP-MS ( ) 7500 ICP-MS (27.12
1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC 4.310 3 ml Syphilis TPAb Alb 2.7 g dl RBC30210 4 ml HBsAg T. bil 2.3 mg dl Hb 11 g dl
2012; 18: 200 207 Necropsy 1 1 1 2 65 11 autoimmune hepatitisaih 14 21 1 5 13 Necropsy CHF1 A1 Kupffer cell hemosiderin Berlin blue KEY WORDS: hemochromatosis, autoimmune hepatitis, liver cirrhosis, necropsy
温泉の化学 １
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
PowerPoint Presentation
東京都実技講習会 骨髄症例 課題 Jo106 症例:60 歳男性 入院時検査所見 CBC WBC 1.1x10 9 /L RBC 2.69x10 12 /L Hb 8.2 g/dl Hct 24.5 % PLT 58x10 9 /L Reti 0.1 % My 2.0 Meta 1.0 St 3.5 Seg 57.5 Mo 8.5 Lym 27.5 生化学 TP 6.3 g/dl ALB 3.5 g/dl
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
頸部リンパ節腫張 のコピー.pptx
17 1cm LMP General : BP110/70 HR60 RR16 T37.2 Eye Oral Neck ( cm Lungs Heart Abd Skin : cm Hb g/dl Ht Plt. /µl WBC /µl Seg Lym Mono AT-Ly Baso Na meq/l K meq/l Cl meq/ L Ca BUN mg/dl Cr mg/ dl GOT IU/L
巻 頭 言
LabClinPract.20138422002 RC.P.C. 33 33 00/4/2511 : 20 4/26 2 34 /34 / 167cm 83kgBMI 29.8 WBC 10 3 /µ l 7.8 13.3 12.0 RBC 10 4 /µ l 542 544 505 HGB g/dl 18.8 15.6 14.4 HCT % 45.9 46.5 42.9 MCV fl 84.6 85.5
診療工房 診診連携機能説明資料 診療工房について 1. 新しい診診連携機能 2. 情報提供 ( 診診送信 ) の仕方 3. 受信確認の仕方 4. システム設定の受信設定タブ 5. 新しいログイン管理 6. 検査データコピー機能ランチャーについて 7. 県中のボタン医師署名システムについて 8. 医師
診療工房 診診連携機能説明資料 診療工房について 1. 新しい診診連携機能 2. 情報提供 ( 診診送信 ) の仕方 3. 受信確認の仕方 4. システム設定の受信設定タブ 5. 新しいログイン管理 6. 検査データコピー機能ランチャーについて 7. 県中のボタン医師署名システムについて 8. 医師署名システムについて WEB 会議について 9.WEB 会議 ( たてやまミーティング ) について疑似
<4D F736F F D F8DCC97918C7B82CC8C8C897490B689BB8A AB8FF382CC908488DA2E646F63>
1 8 4 26 2 ( )(0 20 )(21 64 ) 4 (TP) (GOT GPT) (ALP)(LDH) (Amyl)(CPK) (T cho) (TG) (NEFA) HDL (HDL c) (Na) (K) (cl) (Ca)(P) (Crea)(UA) (Glu) 19 TP GOT LDH T cho NEFA.HDL c K UA GPT LDH CPK T cho TG NEFA
20 57
56 20 57 58 59 12 60 ph 61 62 CCA 63 64 ( 1) 700 7.5 86% 54 17 71 2) 700 6.8 86% 50 15 65 3) 600 700 5.7 84% 36 14 50 550 650 4.2 80% 21 6 27 40 500 3.6 78% 16 7 23 3.6 78% 16 7 23 400 700 4.0 78% 18 7
mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5
Ⅰ. 臨床編 A. 特殊な病態における輸液 1 新生児 未熟児における輸液 実践編症例検討 症例の経過と実際の輸液療法 症例 ❶ 0 主訴 分娩歴 38 4,110 g.4 SD 47.5 cm0.5 SD 3.5 cm0.5 SD 8 1 9 5 現病歴 35 mgdl 60 0 mgdl 入院時現症 150 50 37. 503 mmhg SpO 98FiO 0.1 入院時検査所見 33 mgdl
モーニングレクチャー 腎臓内科編
急性腎障害 (AKI) と急性腎不全 (ARF) について 腎臓内科 髙橋則尋 急性腎障害 (AKI) とは 2004 年 9 月 国際腎臓学会 米国腎臓学会 米国腎臓財団 欧州集中治療学会のメンバーが集まり AKIN:the Acute Kidney Injury Network を設立した 何らかの疾患 障害により数時間 ~ 数日で急激に腎機能が低下する状態を指す 従来の急性腎不全 (ARF)
Microsoft Word - 第1回RCPC案内
第 1 回 Reversed Clinico-pathological Conference (RCPC) のお知らせ主催日本臨床検査医学会教育委員会共催日本臨床検査医学会関東甲信越支部 日本臨床検査医学会教育委員会では 検査結果を正しく解釈することを目的として RCPC を開催します 今回は 第 28 回関東 甲信越支部総会に合わせて下記のように行います 臨床検査専門医更新のための臨床検査領域講習として申請中です
日当直者向け? 血算データの見方 ~ 赤血球減少症 ( 貧血 )~ 船橋市立医療センター福田幸広 貧血とは 末梢血の赤血球成分が不足した状態をさす 判定は 単位血液あたりの赤血球数 ヘモグロビン濃度 ヘマトクリットの3つの指標で行う 酸素運搬能という機能を鑑みれば となる ヘモグロビン濃度による貧血の基準 (WHO による ) 11 12 13 乳幼児 妊婦 高齢者 学童 成人女性 新生児 成人男性
2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
総合_H1-H4_1810
4-6-1 SS30 24 4-261-1 7 1-2-2 8 1-1-10 20 17-1 5 3-17 5 4-9-24 980-6024 330-0843 141-0032 461-0005 564-0053 730-0036 812-0016 Tel 022-722-1710 Tel 048-600-3888 Tel 03-5434-8550 Tel 052-957-3821 Tel 06-6337-8300